Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

March 24, 2025

Study Completion Date

July 31, 2038

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

CLL-1.CAR T cells

"Dose escalation study with 3 dose levels:~DL1: 1x10\^7 cells/m2, DL2: 3x10\^7 cells/m2, DL3: 1x10\^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10\^6 cells/m2"

Trial Locations (1)

77030

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER